INSPHealthcare · Medical DevicesThe 17 Wall Street analysts covering Inspire Medical Systems, Inc. hold a median 12-month price target of $60 — -3.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 2 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Inspire Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Momentum (13): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INSP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −3.4% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | Baird | Maintains | Neutral | $54 → $59 |
| 4 Aug 2026 | Evercore ISI Group | Maintains | In-Line | $40 → $54 |
| 4 Aug 2026 | JP Morgan | Maintains | Neutral | $54 → $60 |
| 4 Aug 2026 | Mizuho | Maintains | Outperform | $55 → $65 |
| 4 Aug 2026 | Oppenheimer | Upgrade | Outperform | $85 |
| 4 Aug 2026 | Piper Sandler | Maintains | Neutral | $55 → $60 |
| 4 Aug 2026 | Truist Securities | Reiterates | Hold | $54 → $62 |
| 28 July 2026 | UBS | Assumes | Sell | $67 → $39 |
| 16 July 2026 | Truist Securities | Maintains | Hold | $50 → $54 |
| 16 July 2026 | Truist Securities | Maintains | Hold | — |
| 1 July 2026 | Freedom Capital Markets | Initiates | Buy | — |
| 23 June 2026 | Evercore ISI Group | Downgrade | In-Line | — |
| 7 May 2026 | Oppenheimer | Maintains | Perform | — |
| 5 May 2026 | Baird | Maintains | Neutral | — |
| 5 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 5 May 2026 | JP Morgan | Maintains | Neutral | — |
| 5 May 2026 | Mizuho | Maintains | Outperform | — |
| 5 May 2026 | Piper Sandler | Downgrade | Neutral | — |
| 5 May 2026 | RBC Capital | Maintains | Sector Perform | — |
| 5 May 2026 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INSP appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 3 Sept 2026, Inspire Medical Systems, Inc. returned −27.4% against +21.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 50% of US stocks
Cheaper than 53% of US stocks
Cheaper than 44% of US stocks
Cheaper than 14% of US stocks
Higher than 18% of US stocks
Higher than 94% of US stocks
Higher than 32% of US stocks
Higher than 77% of US stocks
Higher than 79% of US stocks
Higher than 70% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Inspire Medical Systems, Inc. has a market value of $1.8B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $898.7M. The latest quarter shrank 7.6% year on year.
Net income over the same four quarters: $135.0M, a 15.0% net margin.
Diluted earnings per share, trailing twelve months: $4.62.
Free cash flow in the twelve months to 30 June 2026: $117.1M, after $40.0M of capital spending.
Inspire Medical Systems, Inc. spent $100.0M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 13.9×; forward P/E: 40.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Inspire Medical Systems, Inc. employs 1,333 people — $674K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Inspire Medical Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights that Inspire Medical Systems (INSP) reported earnings 30 days ago and has since declined 4.1%. The article examines what may come next for the stock following the earnings report.
Why it matters — INSP watchers would care because the piece addresses the stock's post-earnings performance and potential factors shaping its outlook.
Inspire Medical Systems, Inc. announced that its management team will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. The company is a medical technology firm focused on minimally invasive solutions for obstructive sleep apnea.
Why it matters — Investors and analysts following INSP will have an opportunity to hear directly from its management at a major industry conference, which can provide insight into the company's strategy and outlook.
Inspire Medical stock has rallied nearly 40% over three months, driven by easing reimbursement pressures, rising adoption of the Inspire V device, and the Project Horizon initiative aimed at longer-term expansion.
Why it matters — A INSP watcher would care because the stock's recent surge reflects improving reimbursement conditions, growing device adoption, and a long-term growth strategy.
Zacks Investment Research highlights Inspire Medical Systems' Inspire V adoption, clinical evidence, and the underpenetrated obstructive sleep apnea market as supporting growth. The report acknowledges ongoing coding and reimbursement headwinds the company faces.
Why it matters — The piece points to drivers of INSP's growth potential while flagging reimbursement challenges, giving investors context on factors that could influence the company's performance.
Zacks Investment Research added Inspire Medical Systems (INSP) to its Zacks Rank #1 (Strong Buy) List on August 18, 2026, alongside ALGT, HMC, AII and ALL.
Why it matters — An INSP watcher would care because the company received a Strong Buy ranking from Zacks, which signals positive analyst sentiment toward the stock.
The 17 Wall Street analysts covering Inspire Medical Systems, Inc. have a median 12-month price target of $60, with estimates ranging from $40 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Inspire Medical Systems, Inc., 4 rate it a Buy, 11 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Inspire Medical Systems, Inc. 81 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 2 Sept 2026, Inspire Medical Systems, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies -3.4% from the last close, and Ticker Nerd's factor model ranks Inspire Medical Systems, Inc. 81 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Inspire Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $85 over the next 12 months.
Inspire Medical Systems, Inc. returned -27.4% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Inspire Medical Systems, Inc. is a medical technology company focused on minimally invasive solutions for obstructive sleep apnea.
The most recent item we track (Zacks Investment Research, 2 Sept 2026): "Why Is Inspire (INSP) Down 4.1% Since Last Earnings Report?". Zacks Investment Research highlights that Inspire Medical Systems (INSP) reported earnings 30 days ago and has since declined 4.1%. The article examines what may come next for the stock following the earnings report.
Inspire Medical Systems, Inc. is a medical technology company focused on minimally invasive solutions for obstructive sleep apnea. Its core product is the Inspire system, an implantable neurostimulation therapy that monitors breathing during sleep and delivers mild hypoglossal nerve stimulation to help maintain an open airway. The company serves patients with moderate to severe obstructive sleep apnea who are seeking an alternative to traditional mask-based treatments, and its offerings are used in hospitals, ambulatory surgery centers, sleep centers, and ENT care pathways. Inspire Medical Systems operates in the United States and selected international markets, with a business centered on device commercialization, physician education, and related patient support services. The company is headquartered in Golden Valley, Minnesota, and remains a specialized player in the sleep medicine and neuromodulation markets.
CEO Mr. Timothy P. Herbert · 1,333 employees · United States · https://www.inspiresleep.com
